Moderna received a refusal-to-file (RTF) letter for its next-generation mRNA flu vaccine, the FDA citing concerns over the trial’s control arm design. Analysts warn the decision may complicate Moderna’s flu-COVID combination strategy, with policy shifts suggesting increased scrutiny of mRNA platforms in the U.S.

This week we've kept Eyes On the MFN and Tariff news, plus the Moderna x HHS Break-up and the Lilly x SiteOne Deal. The BioPharma Marketplace is in flux and we're watching to see how everyone is adapting and re-aligning their strategies.

We've had Eyes On recent news further clarifying company restructures. In the midst of refining pipelines, and cutting corporate spending ..

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...